2.24BMarket Cap
LossP/E TTM
Key Figures
5.940Open
6.280High
5.62MVolume
LossP/E TTM
29.53P/E Dynamic
--Dividend TTM
1.59%Turnover Ratio
5.940Prev. Close
5.920Low
23.39MTurnover
LossP/E Static
106.12P/B
0.00%Div Yield TTM
-152.89%ROA
5.46552wk High
1.27Volume Ratio
-126.23MNet Profit
353.91MShares
-1.2108EPS TTM
1.07Beta
-12418.40%ROE
1.28052wk Low
6.06%Amplitude
88.99%Gross Margin
2.24BMarket Cap
1.22Reward/Risk
4.99%Risk Rate
Currency: USD Updated: 2026-07-31 Key Insights
Precigen Inc's fundamentals are relatively stable, and its growth potential is high.Its valuation is considered fairly valued, ranking 49 out of 155 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 12.50.In the medium term, the stock price is expected to trend up.Despite a good stock market performance and outperforming fundamentals over the past month, the technicals don't support the current trend.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Support & Resistance

Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Precigen Inc Highlights
StrengthsRisks
Precigen Inc News
More news coming soon, stay tuned...
Earnings Forecast
Strong Buy
Buy
Hold
Sell
Strong Sell
Indicators
Financial Indicators
EPS

Relevant data have not been disclosed by the company yet.
Total revenue

Relevant data have not been disclosed by the company yet.
Precigen Inc Info
Precigen, Inc. is a discovery and clinical-stage biopharmaceutical company developing gene and cell therapies for improving outcomes for patients with unmet medical needs. The Company’s proprietary technology platforms develop product candidates designed to target urgent and intractable diseases in its core therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. It has developed a pipeline of therapies across multiple indications. The Company’s segments include Biopharmaceuticals and Exemplar. The Biopharmaceuticals segment is primarily comprised of the Company's legal entities as well as royalty interests in therapeutics and therapeutic platforms from companies not controlled by the Company. The Exemplar is composed of Exemplar Genetics LLC, doing business as Precigen Exemplar, its wholly owned subsidiary focused on developing research models and services for healthcare research applications.
Ticker SymbolPGEN
CompanyPrecigen Inc
CEOSabzevari (Helen)
Websitehttps://precigen.com/
Shareholders
FAQs
What is the current price of Precigen Inc (PGEN)?
The current price of Precigen Inc (PGEN) is 6.27.
What is the symbol of Precigen Inc?
The ticker symbol of Precigen Inc is PGEN.
What is the 52-week high of Precigen Inc?
The 52-week high of Precigen Inc is 5.46.
What is the 52-week low of Precigen Inc?
The 52-week low of Precigen Inc is 1.28.
What is the market capitalization of Precigen Inc?
The market capitalization of Precigen Inc is 2.22B.
Is Precigen Inc (PGEN) currently rated as Buy, Hold, or Sell?
According to analysts, Precigen Inc (PGEN) has an overall rating of Buy, with a price target of 12.50.
What is the Earnings Per Share (EPS TTM) of Precigen Inc (PGEN)?
The Earnings Per Share (EPS TTM) of Precigen Inc (PGEN) is -1.37.